International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)

File Size Format
71334_1.pdf 241Kb Adobe PDF View
Title International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)
Author Berruti, Alfredo; Generali, Daniele; Kaufmann, Manfred; Puztai, Lajos; Curigliano, Giuseppe; Aglietta, Massimo; Gianni, Luca; Miller, William R.; Untch, Michael; Sotiriou, Christos; Daidone, Mariagrazia; Conte, PierFranco; Kennedy, Derek; Damia, Giovanna; Petronini, Piergiorgio; Cosimo, Serena Di; Bruzzi, Paolo; Dowsett, Mitch; Desmedet, Christine; Mansel, Robert E.; Olivetti, Lucio; Tondini, Carlo; Sapino, Anna; Fenaroli, Privato; Tortora, Gianpaolo; Thorne, Hather; Bertolini, Francesco; Ferrozzi, Francesco; Danova, Marco; et al.
Journal Name Journal of the National Cancer Institute Monographs
Year Published 2011
Place of publication United States
Publisher Oxford University Press
Abstract A panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic treatment (PST) either in clinical routine or research practice. The attainment of pathological complete response (pCR), defined as no residual invasive tumor in the surgical specimens both in breast and in axillary nodes, is one of the main goals of PST and pCR can be used as the primary objective in prospective clinical trials. However, pCR is not a reliable end-point with all treatment approaches and alternatives such as Ki67 index of the residual invasive disease or after 2 weeks of PST are also potential end points. PST has several advantages: breast conservation and the unique opportunity to obtain information on the interaction between treatment and tumor biology. Changes in tumor biology after PST are an early phenomenon so an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials.
Peer Reviewed Yes
Published Yes
Alternative URI http://dx.doi.org/10.1093/jncimonographs/lgr037
Copyright Statement Copyright 2011 Oxford University Press. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journal of the National Cancer Institute (JNCI) following peer review. The definitive publisher-authenticated version, International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010), Journal of the National Cancer Institute (JNCI), Vol. 2011(43), 2011, pp. 147-151 is available online at: http://dx.doi.org/10.1093/jncimonographs/lgr037.
Volume 2011
Issue Number 43
Page from 147
Page to 151
ISSN 1052-6773
Date Accessioned 2011-11-01
Date Available 2013-09-01T23:16:23Z
Language en_US
Research Centre Eskitis Institute for Drug Discovery
Faculty Faculty of Science, Environment, Engineering and Technology
Subject Cancer Diagnosis; Cancer Therapy (excl Chemotherapy and Radiation Therapy)
URI http://hdl.handle.net/10072/42282
Publication Type Journal Articles (Refereed Article)
Publication Type Code c1

Show simple item record

Griffith University copyright notice